(MENAFN- EIN Presswire) Immune Checkpoint Inhibitor Market
PORTLAND, OR, UNITED STATES, May 26, 2023 /einpresswire.com / -- The immune checkpoint inhibitor market refers to the market for drugs that block checkpoint proteins on T cells, allowing the immune system to better recognize and attack cancer cells. These drugs have been a major breakthrough in cancer treatment, with many patients experiencing long-term remission from previously untreatable cancers. The market includes a variety of drugs targeting different checkpoint proteins, as well as combination therapies and biosimilars.
According to the report, the global immune checkpoint inhibitors industry generated $34.9 billion in 2021, and is anticipated to generate $155.1 billion by 2031, witnessing a CAGR of 16.1% from 2022 to 2031.
Download Sample Report :
The global immune checkpoint inhibitor market is expected to experience significant growth in the coming years due to factors such as increasing prevalence of cancer, growing adoption of immune checkpoint inhibitors in cancer treatment, and the development of new checkpoint inhibitors and combination therapies. Additionally, factors such as the increasing geriatric population and the rising demand for personalized medicine are expected to drive demand for immune checkpoint inhibitors.
Prime determinants of growth:
Rise in incidence of cancer across the world, surge in global geriatric population, and supportive reimbursement policies for immune checkpoint inhibitors drive the growth of the global immune checkpoint inhibitors market. On the other hand, high cost of immune checkpoint inhibitors impedes the growth to some extent. However, an increase in the number of pipeline drugs is expected to create lucrative opportunities in the industry.
What is the Impact of Covid-19 Pandemic on Immune Checkpoint Inhibitor Market Globally?
The outbreak of the Covid-19 pandemic had a negative impact on the global immune checkpoint inhibitors market. This is owing to a decline in the number of cancer patient visits in hospitals and clinics for immune checkpoint inhibitor therapy (ICI) which, in turn, gave way to a reduced demand of immune checkpoint inhibitors products.
However, the market is anticipated to get back on track soon. This is attributed to the increase in the prevalence of cancer and chronic diseases as well as an increase in the demand for novel drug therapies for the treatment of cancer.
Procure Complete Report (200 Pages PDF with Insights, Charts, Tables, and Figures) @
The PD-1 inhibitor segment to maintain its leadership status throughout the forecast period
The PD-1 inhibitor segment accounted for around three-fourths of the total immune checkpoint inhibitors market share in 2021, and is expected to rule the roost by 2031, owing to the increase in prevalence of various type of cancer along with a rise in geriatric population across the world. The PD-L1 inhibitor segment, on the other hand, would garner the fastest CAGR of 15.6% throughout the forecast period, owing to a rise in the number of PD-L1 drugs in pipeline.
The lung cancer segment to maintain its leadership status throughout the forecast period
The lung cancer segment contributed to more than one-third of the total immune checkpoint inhibitors market revenue in 2021, and is projected to lead the trail by 2031. The same segment would also exhibit the fastest CAGR of 17.0% during the forecast period, owing to the surge in the prevalence of lung cancer of across the world.
For Purchase Enquiry at:
North America to maintain its dominance by 2031
Based on region, the market across North America held the major share in 2020, garnering more than three-fifths of the global immune checkpoint inhibitors market and is estimated to maintain its leadership status throughout the forecast period, owing to high expenditure on R&D, presence of major players & their product availability, and well-established healthcare infrastructure in the region. The Asia-Pacific region, however, would manifest the fastest CAGR of 18.4% throughout the forecast period, owing to the improvement in R&D facilities, available disposable income, and rapidly developing economic conditions in the region.
Immune Checkpoint Inhibitor Market Leading Market Players: -
AstraZeneca PLC
Bristol Myers Squibb Company
Eli Lilly and Company
GlaxoSmithKline PLC
F. Hoffmann-La Roche Ltd.
Sanofi
Merck & Co. Inc.
Merck KGaA
BeiGene Ltd.
Shanghai Jhunsi Biosciences Ltd.
The report provides a detailed analysis of these key players of the global immune checkpoint inhibitors market. These players have adopted different strategies such as new product launches, collaborations, expansion, joint ventures, agreements, and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.
Trending Reports in Healthcare Industry:
Central Lab Market Size:
Gene Synthesis Market Share:
Contact:
David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
David Correa
Allied Analytics LLP
+ 1-800-792-5285
email us here